The Danish company Biosyntia has been chosen as a contender for the ‘Most Innovative EU Biotech SME’ award because of its unique fermentation solutions provided to chemical manufacturing companies. It is especially Biosyntia’s core technology RIBOSELECT that has caught EuropaBio’s attention, as the technology accelerates the discovery of novel enzymes and pathways required for cell factory development and cell factory optimization based on E.coli and yeast.
High standards in Danish biotech
“It is gratifying to see that Biosyntia has been nominated to win the fifth annual Most Innovative EU Biotech SME. This goes to show that we have innovation companies in Denmark of highest international standard”, says Tine Hartmann Nielsen, Team Leader for Life Sciences at Invest in Denmark.
The top five candidates for this year’s award were selected from a total of 35 applicants. Biosyntia will compete against the UK-based healthcare biotech company, Autifony; the Italian industrial biotech company, Bio-on; the French biopharmaceutical company, Erytech Pharma; and the Dutch biotechnology company, to-BBB.
This year’s annual EuropaBio award ceremony will take place during the European Biotech Week on 8 October 2014 in Brussels.
EuropaBio is the European Association for Bioindustries. The association brings together bioscience companies from all fields of research & development, testing, manufacturing and distribution of biotechnology products. Its corporate, associate and national association members are involved in all phases, including commercialisation of biotechnology products and processes, and have a wide range of activities, such as human and animal health care, diagnostics, bio-informatics, chemicals, crop protection, agriculture, food and environmental products and services.